StocksMedium•13 November 2026•
1 min read
Milestone Pharmaceuticals Stock Rises 6% on Revenue Beat
Key Facts
1Milestone Pharmaceuticals stock rose 6% after reporting financial results that beat revenue estimates.
Milestone Pharmaceuticals stock rose 6% after reporting financial results that beat revenue estimates. Investing.com Canada reported that the rally followed the release of Q3 2026 earnings, which showed revenue growth exceeding market expectations.
The positive momentum in the stock price was triggered by the Q3 revenue beat and progress surrounding the launch of the CARDAMYST nasal spray. The price action on November 13, 2026, reflected a bullish market reaction to the company's financial performance relative to initial forecasts.